Specialty Pharmacy

A new report projects health insurance coverage losses between 2018 and 2028 for people under age 65 as a result of changes to the Affordable Care Act (ACA) by the Trump administration.

A new 5-part video series released by the FDA is part of a larger education and outreach effort about biosimilars and interchangeable products.

FDA officials have approved pegvaliase-pqpz (Palynziq, BioMarin Pharmaceutical) for adults with a rare and serious genetic disease, phenylketonuria (PKU).

Patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who were treated with inotuzumab ozogamicin (InO) indicated better quality of life, functioning, and symptom scores compared with patients receiving standard-of-care chemotherapies.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Researchers have identified a gene associated with the body’s circadian rhythm that may play a role in the development of breast cancer.

A look at last week's top stories in the world of pharmacy.

Two studies assessed prostate specific antigen (PSA) progression in patients treated with apalutamide (Erleada, Janssen) and the association between PSA doubling time and survival.

Top news of the day from across the health care landscape.

Brain damage can begin early in infection, particularly during untreated infection, and can cause cognitive impairment.

The FDA is taking new steps to ensure products being marketed to protect consumers from the sun’s harmful effects deliver on their promises, starting with warning letters sent to companies marketing products with unproven claims.

Ixekizumab (Taltz, Eli Lilly) is the first and only treatment approved by the FDA for moderate-to-severe plaque psoriasis that includes data on psoriasis involving the genital area in its label.

Data from two phase 3 studies found that emicizumab-kxwh (Hemlibra) prophylaxis controlled bleeds in patients with hemophilia A.

Patients with severe asthma who were treated with dupilumab experienced a reduction in severe exacerbation risk, improved lung function, and reduced dependence on oral corticosteroids.

Top news of the day from across the health care landscape.

Rucaparib, an (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of ovarian cancer, may have potential clinical benefit for patients with advanced pancreatic cancer and a BRCA1/2 mutation.

Achilles Alon, PharmD, RPh, director of Specialty Pharmacy, co-owner of ACE-Rx Specialty Pharmacy, discusses the concerns regarding DIR fees and the impact it may have.

The FDA has announced its approval of avatrombopag (Doptelet, AkaRx) tablets to treat low blood platelet count in adults with chronic liver disease (CLD) who are scheduled to undergo a medical or dental procedure.

Patients with glucocorticoid-induced osteoporosis on glucocorticoid therapy who received denosumab (Prolia) had greater gains in bone mineral density in a phase 3 trial.

Officials with the FDA alerted health care professionals about reduced efficacy for some patients taking pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for metastatic urothelial cancer in ongoing clinical trials.

Top news of the day from across the health care landscape.

Antibiotic-resistant Acinetobacter baumannii infections put children with compromised immune systems in health care settings at greater risk of infections of the lung, urinary tract, and other sites.

Pharmacies are increasingly using collected health data to target advertising to customers or identify needs and purchase patterns.

Mepolizumab (Nucala) consistently improves exacerbation reduction and asthma control in patients with severe eosinophilic asthma.

Opioid-related pharmaceutical payments were associated with an increase in the number of opioids prescribed.

Top news of the day from across the health care landscape.

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses the growth of pharmacy accreditation offerings.